Filtered By:
Management: Hospitals
Countries: UK Health

This page shows you your search results in order of relevance. This is page number 6.

Order by Relevance | Date

Total 314 results found since Jan 2013.

How do we ensure that more patients receive stroke thrombectomy in the UK?
Br J Hosp Med (Lond). 2023 May 2;84(5):1-4. doi: 10.12968/hmed.2023.0111. Epub 2023 May 22.ABSTRACTStroke is a major cause of death in the UK. Mechanical thrombectomy is the most effective treatment for large vessel ischaemic strokes. Despite this, very few patients in the UK receive mechanical thrombectomy. This editorial explores the main barriers to mechanical thrombectomy use and mechanisms to improve uptake.PMID:37235673 | DOI:10.12968/hmed.2023.0111
Source: British Journal of Hospital Medicine - May 26, 2023 Category: Internal Medicine Authors: Richard J Jabbour Helen Routledge Nick Curzen Source Type: research

Dog Ownership Linked To 24% Lower Risk Of Dying Early, Research Shows
(CNN) — Need an excellent reason to add a dog to your life? How about living longer? “Our analysis found having a dog is actually protective against dying of any cause,” said Mount Sinai endocrinologist Dr. Caroline Kramer, lead author of a new systematic review of nearly 70 years of global research published Tuesday in “Circulation,” a journal of the American Heart Association. The review of the health benefits of man’s best friend analyzed research involving nearly 4 million people in the United States, Canada, Scandinavia, New Zealand, Australia and the United Kingdom. “Dog owne...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - October 8, 2019 Category: Consumer Health News Authors: Health – CBS Boston Tags: Featured Health News Offbeat Syndicated CBSN Boston CNN Dogs Source Type: news

FDA Approves Two New Indications for XARELTO ® (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients
RARITAN, NJ, Dec. 20, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved two pediatric indications for XARELTO® (rivaroxaban): the treatment of venous thromboembolism (VTE, or blood clots) and reduction in the risk of recurrent VTE in patients from birth to less than 18 years after at least five days of initial parenteral (injected or intravenous) anticoagulant treatment; and thromboprophylaxis (prevention of blood clots and blood-clot related events) in children aged two years and older with congenital heart disease who have...
Source: Johnson and Johnson - December 21, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news